Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.

Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW.

PLoS One. 2019 Jan 14;14(1):e0210730. doi: 10.1371/journal.pone.0210730. eCollection 2019.

2.

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice.

Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Onco Targets Ther. 2018 Dec 24;12:225-231. doi: 10.2147/OTT.S187621. eCollection 2019.

3.

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial.

Kim Y, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Lee SJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

J Gastric Cancer. 2018 Dec;18(4):348-355. doi: 10.5230/jgc.2018.18.e34. Epub 2018 Nov 16.

4.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2018 Dec 31. pii: theoncologist.2018-0838. doi: 10.1634/theoncologist.2018-0838. [Epub ahead of print]

PMID:
30598500
5.

Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.

Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley ER, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V.

Immunity. 2018 Dec 18;49(6):1191. doi: 10.1016/j.immuni.2018.12.009. No abstract available.

PMID:
30566884
6.

Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.

Yoo C, Park JW, Kim YJ, Kim DY, Yu SJ, Lim TS, Lee SJ, Ryoo BY, Lim HY.

Invest New Drugs. 2018 Dec 7. doi: 10.1007/s10637-018-0707-5. [Epub ahead of print]

PMID:
30523474
7.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Oh SY, Lee S, Huh SJ, Lee J, Kim ST, Park SH, Lim HY, Kang WK, Kang BW, Kim JG, Lee HJ, Kim JH, Kang JH, Kim H.

Cancer Chemother Pharmacol. 2018 Dec 8. doi: 10.1007/s00280-018-3753-y. [Epub ahead of print]

PMID:
30535535
8.

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.

Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK.

Cancer Res Treat. 2018 Nov 21. doi: 10.4143/crt.2018.379. [Epub ahead of print]

9.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.

Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, Lim HY, Kang WK, Park JO.

BMC Cancer. 2018 Nov 12;18(1):1103. doi: 10.1186/s12885-018-4995-0.

10.

Comprehensive transcriptome analysis of Sarcophaga peregrina, a forensically important fly species.

Kim JY, Lim HY, Shin SE, Cha HK, Seo JH, Kim SK, Park SH, Son GH.

Sci Data. 2018 Nov 6;5:180220. doi: 10.1038/sdata.2018.220.

11.

A comparison of global coagulation assays between normal controls and patients with thrombocytopenia.

Lim HY, Leung P, Manitta V, Nandurkar H, Ho P.

Int J Lab Hematol. 2018 Oct 26. doi: 10.1111/ijlh.12941. [Epub ahead of print]

PMID:
30365212
12.

Increased p63 Expression in Canine Perianal Gland Tumours.

Kim SH, Seung BJ, Cho SH, Lim HY, Park HM, Sur JH.

J Vet Res. 2018 Oct 24;62(2):229-235. doi: 10.2478/jvetres-2018-0020. eCollection 2018 Jun.

13.

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node‒Positive Gastric Cancer Treated with Different Adjuvant Protocols.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K.

Cancer Res Treat. 2018 Oct 1. doi: 10.4143/crt.2018.401. [Epub ahead of print]

14.

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation.

Lee T, Kim K, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO, Kim ST.

J Cancer. 2018 Sep 8;9(18):3394-3399. doi: 10.7150/jca.26068. eCollection 2018.

15.

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.

Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M.

Invest New Drugs. 2018 Dec;36(6):1072-1084. doi: 10.1007/s10637-018-0658-x. Epub 2018 Sep 10.

PMID:
30198057
16.

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial.

Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.

J Cancer. 2018 Jul 30;9(16):2910-2915. doi: 10.7150/jca.24948. eCollection 2018.

17.

Expression of Oestrogen Receptor, Progesterone Receptor and Akt in Canine Circumanal Gland Tumours.

Kim SH, Seung BJ, Cho SH, Lim HY, Hwang JH, Sur JH.

J Comp Pathol. 2018 Jul;162:59-65. doi: 10.1016/j.jcpa.2018.06.006. Epub 2018 Jul 18.

PMID:
30060844
18.

Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.

Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley RE, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V.

Immunity. 2018 Aug 21;49(2):326-341.e7. doi: 10.1016/j.immuni.2018.06.008. Epub 2018 Jul 24. Erratum in: Immunity. 2018 Dec 18;49(6):1191.

PMID:
30054204
19.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim HS, Ahn S.

Radiother Oncol. 2018 Nov;129(2):306-312. doi: 10.1016/j.radonc.2018.07.002. Epub 2018 Jul 20.

PMID:
30037498
20.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK.

Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.

PMID:
30013197
21.

Effects of isometric, eccentric, or heavy slow resistance exercises on pain and function in individuals with patellar tendinopathy: A systematic review.

Lim HY, Wong SH.

Physiother Res Int. 2018 Oct;23(4):e1721. doi: 10.1002/pri.1721. Epub 2018 Jul 4. Review.

PMID:
29972281
22.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

PMID:
29950351
23.

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.

Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY.

Cancer Res Treat. 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print]

24.

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.

Kim ST, Kim HK, Lee J, Park SH, Lim HY, Park YS, Kang WK, Park JO.

J Cancer. 2018 Apr 19;9(10):1791-1796. doi: 10.7150/jca.25132. eCollection 2018.

25.

Maximising yield of peripheral blood flow cytometry for chronic lymphoproliferative disorders.

Lim HY, Hong FS.

Int J Lab Hematol. 2018 May 23. doi: 10.1111/ijlh.12861. [Epub ahead of print]

PMID:
29790655
26.

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.

J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.

27.

Potential Functional Byproducts from Guava Purée Processing.

Lim SY, Tham PY, Lim HYL, Heng WS, Chang YP.

J Food Sci. 2018 Jun;83(6):1522-1532. doi: 10.1111/1750-3841.14155. Epub 2018 May 10.

PMID:
29745989
28.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.

Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

PMID:
29659672
29.

Expanding Actin Rings Zipper the Mouse Embryo for Blastocyst Formation.

Zenker J, White MD, Gasnier M, Alvarez YD, Lim HYG, Bissiere S, Biro M, Plachta N.

Cell. 2018 Apr 19;173(3):776-791.e17. doi: 10.1016/j.cell.2018.02.035. Epub 2018 Mar 22.

PMID:
29576449
30.

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.

Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Clin Colorectal Cancer. 2018 Sep;17(3):165-169. doi: 10.1016/j.clcc.2018.02.013. Epub 2018 Mar 2.

31.

Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism.

Lim HY, Nandurkar H, Ho P.

Semin Thromb Hemost. 2018 Apr;44(3):261-266. doi: 10.1055/s-0038-1637750. Epub 2018 Mar 20. Review.

PMID:
29558778
32.

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.

Lee J, Kim ST, Park S, Lee S, Park SH, Park JO, Lim HY, Ahn H, Bok H, Kim KM, Ahn MJ, Kang WK, Park YS.

Clin Colorectal Cancer. 2018 Jun;17(2):140-146. doi: 10.1016/j.clcc.2018.01.005. Epub 2018 Jan 31.

PMID:
29551559
33.

An evaluation of global coagulation assays in myeloproliferative neoplasm.

Lim HY, Ng C, Rigano J, Tacey M, Donnan G, Nandurkar H, Ho P.

Blood Coagul Fibrinolysis. 2018 Apr;29(3):300-306. doi: 10.1097/MBC.0000000000000724.

PMID:
29538005
34.

The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex.

Jang J, Chung S, Choi Y, Lim HY, Son Y, Chun SK, Son GH, Kim K, Suh YG, Jung JW.

Life Sci. 2018 May 1;200:49-55. doi: 10.1016/j.lfs.2018.03.022. Epub 2018 Mar 10.

PMID:
29534992
35.

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, Dickinson M, Campbell P, Hempton J, King H, Dowsing C, Bergin K, Muir S, Gibbs S, Grigg A.

Bone Marrow Transplant. 2018 Sep;53(9):1116-1123. doi: 10.1038/s41409-018-0152-2. Epub 2018 Mar 9.

PMID:
29523889
36.

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer.

Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY.

Transl Oncol. 2018 Apr;11(2):353-357. doi: 10.1016/j.tranon.2018.01.007. Epub 2018 Feb 20.

37.

A point-of-care diagnostic system to influenza viruses using chip-based ultra-fast PCR.

Kwon SH, Lee S, Jang J, Seo Y, Lim HY.

J Med Virol. 2018 Jun;90(6):1019-1026. doi: 10.1002/jmv.25046. Epub 2018 Feb 27.

PMID:
29424457
38.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.

Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J.

Ann Oncol. 2018 Apr 1;29(4):1037-1048. doi: 10.1093/annonc/mdy034.

39.

CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors.

Seung BJ, Lim HY, Shin JI, Kim HW, Cho SH, Kim SH, Sur JH.

Vet Pathol. 2018 May;55(3):417-424. doi: 10.1177/0300985817750457. Epub 2018 Jan 17.

PMID:
29343199
40.

Streptococcus Constellatus Spondylodiscitis in a Teenager: A Case Report.

Lim SW, Lim HY, Kannaiah T, Zuki Z.

Malays Orthop J. 2017 Nov;11(3):50-52. doi: 10.5704/MOJ.1711.004.

41.

Elevated CEA is associated with worse survival in recurrent rectal cancer.

Cho WK, Choi DH, Park HC, Park W, Yu JI, Park YS, Park JO, Lim HY, Kang WK, Kim HC, Cho YB, Yun SH, Lee WY.

Oncotarget. 2017 Nov 18;8(62):105936-105941. doi: 10.18632/oncotarget.22511. eCollection 2017 Dec 1.

42.

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.

Kim JE, Kim Y, Li G, Kim ST, Kim K, Park SH, Park JO, Park YS, Lim HY, Lee H, Sohn TS, Kim KM, Kang WK, Lee J.

Oncotarget. 2017 Nov 11;8(62):105727-105734. doi: 10.18632/oncotarget.22394. eCollection 2017 Dec 1.

43.

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.

Lee JY, Kim K, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Kwon GY, Kim KM, Lee J, Lim HY, Park SH.

Transl Oncol. 2018 Feb;11(1):37-42. doi: 10.1016/j.tranon.2017.10.008. Epub 2017 Nov 21.

44.

Directional associations between memory impairment and depressive symptoms: data from a longitudinal sample and meta-analysis.

Yu J, Lim HY, Abdullah FNDM, Chan HM, Mahendran R, Ho R, Kua EH, Power MJ, Feng L.

Psychol Med. 2018 Jul;48(10):1664-1672. doi: 10.1017/S0033291717003154. Epub 2017 Nov 8.

PMID:
29113607
45.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.

Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.

46.

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.

Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Oncotarget. 2017 May 25;8(43):73974-73980. doi: 10.18632/oncotarget.18168. eCollection 2017 Sep 26.

47.

Comparison of Five Protein Engineering Strategies for Stabilizing an α/β-Hydrolase.

Jones BJ, Lim HY, Huang J, Kazlauskas RJ.

Biochemistry. 2017 Dec 19;56(50):6521-6532. doi: 10.1021/acs.biochem.7b00571. Epub 2017 Nov 14.

48.

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.

Kim ST, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.

J Cancer. 2017 Aug 23;8(14):2809-2815. doi: 10.7150/jca.18286. eCollection 2017.

49.

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.

Kim JS, Kim JE, Kim K, Lee J, Park JO, Lim HY, Park YS, Kang WK, Kim ST.

J Cancer. 2017 Aug 22;8(14):2713-2719. doi: 10.7150/jca.19458. eCollection 2017.

50.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

Supplemental Content

Loading ...
Support Center